Tim Daniel Rose
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tim Daniel Rose has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Josch Konstantin Pauling
LipiTUM, TUM School of Life Sciences, Technical University of Munich, 85354 Freising, Germany
7 shared publications - Nikolai Köhler
LipiTUM, Chair of Experimental Bioinformatics, TUM School of Life Sciences, Technical University of Munich, 85354 Freising, Germany
5 shared publications Jan Baumbach
Chair of Computational Systems Biology, University of Hamburg, 22607 Hamburg, Germany
3 shared publications- Jan Baumbach
Institute for Computational Systems Biomedicine, University of Hamburg , Hamburg 22761
3 shared publications - Julian Späth
Institute for Computational Systems Biology University of Hamburg Hamburg Germany
3 shared publications - Andreas Pichlmair
Institute of Virology, School of Medicine and Health, Technical University of Munich, Munich, Germany
2 shared publications
Latest Publications
- Open Access
- 30 January 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (5) , 101340
Metabolomic liquid biopsy dynamics predict early-stage HCC and actionable candidates of human hepatocarcinogenesis
- 30 January 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (5) , 101340
Open AccessMetabolomic liquid biopsy dynamics predict early-stage HCC and actionable candidates of human hepatocarcinogenesis
- Open Access
Identification and Integration of Key-Metabolic Reactions from Untargeted Metabolomics
Metabolomics has become increasingly popular in biological and biomedical research, especially for multi-omics studies, due to the many associations of metabolism with diseases. This development is driven by improvements in metabolite identification and generating large amounts of data, increasing the need for computational solutions for data interpretation. In particular, only few computational approaches directly generating mechanistic hypotheses exist, making the biochemical interpretation of metabolomics data difficult. We present mantra , an approach to estimate how metabolic reactions change their activity between biological conditions without requiring absolute quantification of metabolites. Starting with a data-specific metabolic network we utilize linear models between substrates and products of a metabolic reaction to approximate deviations in activity. The obtained estimates can subsequently be used for network enrichment and integration with other omics data. By applying mantra to untargeted metabolomics measurements of Triple-Negative Breast Cancer biopsies, we show that it can accurately pinpoint biomarkers. On a dataset of stool metabolomics from Inflammatory Bowel Disease patients, we demonstrate that predictions on our proposed reaction metric generalize to an independent validation cohort and that it can be used for multi-omics network integration. By allowing mechanistic interpretation we facilitate knowledge extraction from metabolomics experiments.
Open AccessIdentification and Integration of Key-Metabolic Reactions from Untargeted Metabolomics
Metabolomics has become increasingly popular in biological and biomedical research, especially for multi-omics studies, due to the many associations of metabolism with diseases. This development is driven by improvements in metabolite identification and generating large amounts of data, increasing the need for computational solutions for data interpretation. In particular, only few computational approaches directly generating mechanistic hypotheses exist, making the biochemical interpretation of metabolomics data difficult. We present mantra , an approach to estimate how metabolic reactions change their activity between biological conditions without requiring absolute quantification of metabolites. Starting with a data-specific metabolic network we utilize linear models between substrates and products of a metabolic reaction to approximate deviations in activity. The obtained estimates can subsequently be used for network enrichment and integration with other omics data. By applying mantra to untargeted metabolomics measurements of Triple-Negative Breast Cancer biopsies, we show that it can accurately pinpoint biomarkers. On a dataset of stool metabolomics from Inflammatory Bowel Disease patients, we demonstrate that predictions on our proposed reaction metric generalize to an independent validation cohort and that it can be used for multi-omics network integration. By allowing mechanistic interpretation we facilitate knowledge extraction from metabolomics experiments.
- Open Access
- 2 January 2023
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 24 (1)
Lipid network and moiety analysis for revealing enzymatic dysregulation and mechanistic alterations from lipidomics data
Lipidomics is of growing importance for clinical and biomedical research due to many associations between lipid metabolism and diseases. The discovery of these associations is facilitated by improved lipid identification and quantification. Sophisticated computational methods are advantageous for interpreting such large-scale data for understanding metabolic processes and their underlying (patho)mechanisms. To generate hypothesis about these mechanisms, the combination of metabolic networks and graph algorithms is a powerful option to pinpoint molecular disease drivers and their interactions. Here we present lipid network explorer (LINEX$^2$), a lipid network analysis framework that fuels biological interpretation of alterations in lipid compositions. By integrating lipid-metabolic reactions from public databases, we generate dataset-specific lipid interaction networks. To aid interpretation of these networks, we present an enrichment graph algorithm that infers changes in enzymatic activity in the context of their multispecificity from lipidomics data. Our inference method successfully recovered the MBOAT7 enzyme from knock-out data. Furthermore, we mechanistically interpret lipidomic alterations of adipocytes in obesity by leveraging network enrichment and lipid moieties. We address the general lack of lipidomics data mining options to elucidate potential disease mechanisms and make lipidomics more clinically relevant.
- 2 January 2023
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 24 (1)
Open AccessLipid network and moiety analysis for revealing enzymatic dysregulation and mechanistic alterations from lipidomics data
Lipidomics is of growing importance for clinical and biomedical research due to many associations between lipid metabolism and diseases. The discovery of these associations is facilitated by improved lipid identification and quantification. Sophisticated computational methods are advantageous for interpreting such large-scale data for understanding metabolic processes and their underlying (patho)mechanisms. To generate hypothesis about these mechanisms, the combination of metabolic networks and graph algorithms is a powerful option to pinpoint molecular disease drivers and their interactions. Here we present lipid network explorer (LINEX$^2$), a lipid network analysis framework that fuels biological interpretation of alterations in lipid compositions. By integrating lipid-metabolic reactions from public databases, we generate dataset-specific lipid interaction networks. To aid interpretation of these networks, we present an enrichment graph algorithm that infers changes in enzymatic activity in the context of their multispecificity from lipidomics data. Our inference method successfully recovered the MBOAT7 enzyme from knock-out data. Furthermore, we mechanistically interpret lipidomic alterations of adipocytes in obesity by leveraging network enrichment and lipid moieties. We address the general lack of lipidomics data mining options to elucidate potential disease mechanisms and make lipidomics more clinically relevant.
- Open Access
- 26 August 2022
- Published by ScienceOpen
Targeting infectious diseases: The CoVex example
In a pandemic, such as the one caused by the coronavirus in 2020, fast action is required to provide insights into the disease mechanisms and to find potential drug targets to slow the progress of the disease and lower mortality. We developed CoVex, an interactive online platform for the exploration of the SARS-CoV-2 host interactome and the identification of drug candidates. CoVex integrates the virus-human protein interactions, human protein-protein interactions, and drug-target interactions, and allows for visual exploration of the data. The exploration is guided by network-based systems medicine algorithms that enable the assembly of ranked lists of candidates for already approved drugs. Unlike novel drugs, approved drugs have the advantage that most of their side effects and contraindications are known. Additionally, they are already available and can be distributed quickly, which makes them promising candidates to stop the uncontrolled spread of the disease early. CoVex is an example of how this could be achieved in future pandemics and provides valuable lessons on what is required in such a situation to maximize the potential of computational approaches that can significantly speed up drug discovery.
- 26 August 2022
- Published by ScienceOpen
Open AccessTargeting infectious diseases: The CoVex example
In a pandemic, such as the one caused by the coronavirus in 2020, fast action is required to provide insights into the disease mechanisms and to find potential drug targets to slow the progress of the disease and lower mortality. We developed CoVex, an interactive online platform for the exploration of the SARS-CoV-2 host interactome and the identification of drug candidates. CoVex integrates the virus-human protein interactions, human protein-protein interactions, and drug-target interactions, and allows for visual exploration of the data. The exploration is guided by network-based systems medicine algorithms that enable the assembly of ranked lists of candidates for already approved drugs. Unlike novel drugs, approved drugs have the advantage that most of their side effects and contraindications are known. Additionally, they are already available and can be distributed quickly, which makes them promising candidates to stop the uncontrolled spread of the disease early. CoVex is an example of how this could be achieved in future pandemics and provides valuable lessons on what is required in such a situation to maximize the potential of computational approaches that can significantly speed up drug discovery.
- Open Access
- 11 April 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (16)
MoSBi: Automated signature mining for molecular stratification and subtyping
Significance: Molecular patient stratification and disease subtyping are ongoing and high-impact problems that rely on the identification of characteristic molecular signatures. Current computational methods show high sensitivity to custom parameterization, which leads to inconsistent performance on different molecular data. Our new method, MoSBi (molecular signature identification using biclustering), 1) enables so far unmatched high performance for stratification and subtyping across datasets of various different biomolecules, 2) provides a scalable solution for visualizing the results and their correspondence to clinical factors, and 3) has immediate practical relevance through its automatic workflow where individual selection, parameterization, screening, and visualization of biclustering algorithms is not required. MoSBi is a major step forward with a high impact for clinical and wet-lab researchers.
- 11 April 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (16)
Open AccessMoSBi: Automated signature mining for molecular stratification and subtyping
Significance: Molecular patient stratification and disease subtyping are ongoing and high-impact problems that rely on the identification of characteristic molecular signatures. Current computational methods show high sensitivity to custom parameterization, which leads to inconsistent performance on different molecular data. Our new method, MoSBi (molecular signature identification using biclustering), 1) enables so far unmatched high performance for stratification and subtyping across datasets of various different biomolecules, 2) provides a scalable solution for visualizing the results and their correspondence to clinical factors, and 3) has immediate practical relevance through its automatic workflow where individual selection, parameterization, screening, and visualization of biclustering algorithms is not required. MoSBi is a major step forward with a high impact for clinical and wet-lab researchers.
- Open Access
Lipid network and moiety analysis for revealing enzymatic dysregulation and mechanistic alterations from lipidomics data
Lipidomics is of growing importance for clinical and biomedical research due to many associations between lipid metabolism and diseases. The discovery of these associations is facilitated by improved lipid identification and quantification. Sophisticated computational methods are advantageous for interpreting such large-scale data for understanding metabolic processes and their underlying (patho)mechanisms. To generate hypothesis about these mechanisms, the combination of metabolic networks and graph algorithms is a powerful option to pinpoint molecular disease drivers and their interactions. Here we present LINEX 2 (Lipid Network Explorer), a lipid network analysis framework that fuels biological interpretation of alterations in lipid compositions. By integrating lipid-metabolic reactions from public databases we generate dataset-specific lipid interaction networks. To aid interpretation of these networks we present an enrichment graph algorithm that infers changes in enzymatic activity in the context of their multispecificity from lipidomics data. Our inference method successfully recovered the MBOAT7 enzyme from knock-out data. Furthermore, we mechanistically interpret lipidomic alterations of adipocytes in obesity by leveraging network enrichment and lipid moieties. We address the general lack of lipidomics data mining options to elucidate potential disease mechanisms and make lipidomics more clinically relevant. Graphical LINEX 2 (Lipid Network Explorer) is a framework to visualize and analyze quantitative lipidomics data. The included algorithms offer new perspectives on the lipidome and can propose potential mechanisms of dysregulation. Using the Reactome and Rhea databases, a comprehensive set of lipid class reactions is included and utilized to map the lipidome on custom data-specific networks. With a novel network enrichment method, enzymatic dysregulation can be recovered from lipidomics data. We validate its usability on data with a central lipid enzymatic deficiency. LINEX 2 is the first tool capable of such analysis and includes complimentary analysis options for structural lipid analysis. It is freely available as a web service ( https://exbio.wzw.tum.de/linex2 ).
Open AccessLipid network and moiety analysis for revealing enzymatic dysregulation and mechanistic alterations from lipidomics data
Lipidomics is of growing importance for clinical and biomedical research due to many associations between lipid metabolism and diseases. The discovery of these associations is facilitated by improved lipid identification and quantification. Sophisticated computational methods are advantageous for interpreting such large-scale data for understanding metabolic processes and their underlying (patho)mechanisms. To generate hypothesis about these mechanisms, the combination of metabolic networks and graph algorithms is a powerful option to pinpoint molecular disease drivers and their interactions. Here we present LINEX 2 (Lipid Network Explorer), a lipid network analysis framework that fuels biological interpretation of alterations in lipid compositions. By integrating lipid-metabolic reactions from public databases we generate dataset-specific lipid interaction networks. To aid interpretation of these networks we present an enrichment graph algorithm that infers changes in enzymatic activity in the context of their multispecificity from lipidomics data. Our inference method successfully recovered the MBOAT7 enzyme from knock-out data. Furthermore, we mechanistically interpret lipidomic alterations of adipocytes in obesity by leveraging network enrichment and lipid moieties. We address the general lack of lipidomics data mining options to elucidate potential disease mechanisms and make lipidomics more clinically relevant. Graphical LINEX 2 (Lipid Network Explorer) is a framework to visualize and analyze quantitative lipidomics data. The included algorithms offer new perspectives on the lipidome and can propose potential mechanisms of dysregulation. Using the Reactome and Rhea databases, a comprehensive set of lipid class reactions is included and utilized to map the lipidome on custom data-specific networks. With a novel network enrichment method, enzymatic dysregulation can be recovered from lipidomics data. We validate its usability on data with a central lipid enzymatic deficiency. LINEX 2 is the first tool capable of such analysis and includes complimentary analysis options for structural lipid analysis. It is freely available as a web service ( https://exbio.wzw.tum.de/linex2 ).
- Open Access
MoSBi: Automated signature mining for molecular stratification and subtyping
The improving access to increasing amounts of biomedical data provides completely new chances for advanced patient stratification and disease subtyping strategies. This requires computational tools that produce uniformly robust results across highly heterogeneous molecular data. Unsupervised machine learning methodologies are able to discover de-novo patterns in such data. Biclustering is especially suited by simultaneously identifying sample groups and corresponding feature sets across heterogeneous omics data. The performance of available biclustering algorithms heavily depends on individual parameterization and varies with their application. Here, we developed MoSBi (Molecular Signature identification using Biclustering), an automated multi-algorithm ensemble approach that integrates results utilizing an error model-supported similarity network. We evaluated the performance of MoSBi on transcriptomics, proteomics and metabolomics data, as well as synthetic datasets covering various data properties. Profiting from multi-algorithm integration, MoSBi identified robust group and disease specific signatures across all scenarios overcoming single algorithm specificities. Furthermore, we developed a scalable network-based visualization of bicluster communities that support biological hypothesis generation. MoSBi is available as an R package and web-service to make automated biclustering analysis accessible for application in molecular sample stratification.
Open AccessMoSBi: Automated signature mining for molecular stratification and subtyping
The improving access to increasing amounts of biomedical data provides completely new chances for advanced patient stratification and disease subtyping strategies. This requires computational tools that produce uniformly robust results across highly heterogeneous molecular data. Unsupervised machine learning methodologies are able to discover de-novo patterns in such data. Biclustering is especially suited by simultaneously identifying sample groups and corresponding feature sets across heterogeneous omics data. The performance of available biclustering algorithms heavily depends on individual parameterization and varies with their application. Here, we developed MoSBi (Molecular Signature identification using Biclustering), an automated multi-algorithm ensemble approach that integrates results utilizing an error model-supported similarity network. We evaluated the performance of MoSBi on transcriptomics, proteomics and metabolomics data, as well as synthetic datasets covering various data properties. Profiting from multi-algorithm integration, MoSBi identified robust group and disease specific signatures across all scenarios overcoming single algorithm specificities. Furthermore, we developed a scalable network-based visualization of bicluster communities that support biological hypothesis generation. MoSBi is available as an R package and web-service to make automated biclustering analysis accessible for application in molecular sample stratification.
- Open Access
- 28 July 2021
- Published by MDPI AG in Metabolites
- Vol. 11 (8) , 488
Investigating Global Lipidome Alterations with the Lipid Network Explorer
Lipids play an important role in biological systems and have the potential to serve as biomarkers in medical applications. Advances in lipidomics allow identification of hundreds of lipid species from biological samples. However, a systems biological analysis of the lipidome, by incorporating pathway information remains challenging, leaving lipidomics behind compared to other omics disciplines. An especially uncharted territory is the integration of statistical and network-based approaches for studying global lipidome changes. Here we developed the Lipid Network Explorer (LINEX), a web-tool addressing this gap by providing a way to visualize and analyze functional lipid metabolic networks. It utilizes metabolic rules to match biochemically connected lipids on a species level and combine it with a statistical correlation and testing analysis. Researchers can customize the biochemical rules considered, to their tissue or organism specific analysis and easily share them. We demonstrate the benefits of combining network-based analyses with statistics using publicly available lipidomics data sets. LINEX facilitates a biochemical knowledge-based data analysis for lipidomics. It is availableas a web-application and as a publicly available docker container.
- 28 July 2021
- Published by MDPI AG in Metabolites
- Vol. 11 (8) , 488
Open AccessInvestigating Global Lipidome Alterations with the Lipid Network Explorer
Lipids play an important role in biological systems and have the potential to serve as biomarkers in medical applications. Advances in lipidomics allow identification of hundreds of lipid species from biological samples. However, a systems biological analysis of the lipidome, by incorporating pathway information remains challenging, leaving lipidomics behind compared to other omics disciplines. An especially uncharted territory is the integration of statistical and network-based approaches for studying global lipidome changes. Here we developed the Lipid Network Explorer (LINEX), a web-tool addressing this gap by providing a way to visualize and analyze functional lipid metabolic networks. It utilizes metabolic rules to match biochemically connected lipids on a species level and combine it with a statistical correlation and testing analysis. Researchers can customize the biochemical rules considered, to their tissue or organism specific analysis and easily share them. We demonstrate the benefits of combining network-based analyses with statistics using publicly available lipidomics data sets. LINEX facilitates a biochemical knowledge-based data analysis for lipidomics. It is availableas a web-application and as a publicly available docker container.
- 14 January 2021
- Published by Springer Nature in Nature Computational Science
- Vol. 1 (1) , 33-41
Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies
- 14 January 2021
- Published by Springer Nature in Nature Computational Science
- Vol. 1 (1) , 33-41
Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies
- Open Access
- 14 July 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-9
Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing
Coronavirus Disease-2019 (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. Various studies exist about the molecular mechanisms of viral infection. However, such information is spread across many publications and it is very time-consuming to integrate, and exploit. We develop CoVex, an interactive online platform for SARS-CoV-2 host interactome exploration and drug (target) identification. CoVex integrates virus-human protein interactions, human protein-protein interactions, and drug-target interactions. It allows visual exploration of the virus-host interactome and implements systems medicine algorithms for network-based prediction of drug candidates. Thus, CoVex is a resource to understand molecular mechanisms of pathogenicity and to prioritize candidate therapeutics. We investigate recent hypotheses on a systems biology level to explore mechanistic virus life cycle drivers, and to extract drug repurposing candidates. CoVex renders COVID-19 drug research systems-medicine-ready by giving the scientific community direct access to network medicine algorithms. It is available at https://exbio.wzw.tum.de/covex/.
- 14 July 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-9
Open AccessExploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing
Coronavirus Disease-2019 (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. Various studies exist about the molecular mechanisms of viral infection. However, such information is spread across many publications and it is very time-consuming to integrate, and exploit. We develop CoVex, an interactive online platform for SARS-CoV-2 host interactome exploration and drug (target) identification. CoVex integrates virus-human protein interactions, human protein-protein interactions, and drug-target interactions. It allows visual exploration of the virus-host interactome and implements systems medicine algorithms for network-based prediction of drug candidates. Thus, CoVex is a resource to understand molecular mechanisms of pathogenicity and to prioritize candidate therapeutics. We investigate recent hypotheses on a systems biology level to explore mechanistic virus life cycle drivers, and to extract drug repurposing candidates. CoVex renders COVID-19 drug research systems-medicine-ready by giving the scientific community direct access to network medicine algorithms. It is available at https://exbio.wzw.tum.de/covex/.